#United States #Boulder #Lung Cancer #MRD Detection #Foresight CLARITY

Foresight Diagnostics to Present Groundbreaking Clinical Data at IASLC 2025

Foresight Diagnostics, recognized for its pioneering work in ultrasensitive minimal residual disease (MRD) detection, is set to outline significant clinical performance data from its Foresight CLARITY™ platform at the upcoming IASLC 2025 World Conference on Lung Cancer. This international event, organized by the International Association for the Study of Lung Cancer, will occur in Barcelona, Spain, from September 6 to 9, 2025.

During an oral presentation in collaboration with the University Health Network's Princess Margaret Cancer Centre, Foresight Diagnostics will share insights from the ctDNA-Lung DETECT study. This research involved a meticulous analysis of MRD performance in patients diagnosed with stage I lung cancer, utilizing the Foresight CLARITY™ circulating tumor DNA (ctDNA) assay, known for its exceptional sensitivity with a detection limit of less than one part per million.

Key Findings from the Study

The findings from this research are particularly noteworthy:

• - Pre-operative MRD detection was achieved in 68% of cases, indicating a strong ability to identify residual disease prior to surgical intervention.
• - Post-operative detection rates were also commendable at 38%.
• - The clinical sensitivity for detecting relapse at crucial post-surgical milestones was reported at 55%, with patients showing a median lead time of 10 months before clinical recurrence became evident.
• - Importantly, post-operative MRD detection correlated significantly with poorer recurrence-free survival (RFS) outcomes, highlighting a hazard ratio (HR) of 3.14 (p = 0.0425) post-surgery and an even more significant HR of 8.20 (p = 0.0001) at the one-year follow-up.

Insights from Industry Leaders

Dr. Natasha Leighl, the Division Head of Medical Oncology and Hematology at UHN's Princess Margaret Cancer Centre, emphasized the historical challenges of employing ctDNA-MRD assays in early-stage lung cancer due to these tumors' typically limited shedding of ctDNA. However, she noted that the results of their study reveal how ultrasensitive assays like Foresight CLARITY™ can provide actionable insights, possibly guiding personalized treatment strategies for high-risk patients, including potential escalations in adjuvant therapy.

Foresight Diagnostics' CMO and Head of Research, Dr. David Kurtz, expressed enthusiasm about the expanding potential of their technology. Detecting MRD in early-stage lung cancer patients, both before and after surgery, may lead to new clinical applications that are not feasible with current diagnostic tools. He stated, "We look forward to continuing to support innovative studies that advance precision medicine for lung cancer."

Presentation Schedule

The presentation titled “Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC” is scheduled for Sunday, September 7th, 2025, from 3:15 PM to 4:30 PM CEST. It will take place during session MA03, which focuses on new advances in circulating biomarkers.

To connect with the Foresight Diagnostics team at IASLC 2025 or to learn more about their groundbreaking research, interested individuals may reach out via their official contact channels.

About Foresight Diagnostics

Foresight Diagnostics operates as a privately held cancer diagnostics firm and is a CLIA-registered laboratory. Their liquid biopsy technology, Foresight CLARITY™, is a revolutionary assay aimed at measuring minimal residual disease with reported detection capabilities in parts per million. This enhanced sensitivity represents a significant advancement in enabling physicians and biopharmaceutical companies to develop personalized treatment approaches for patients suffering from various malignancies. For further information, visit foresight-dx.com and follow them on platforms such as X, LinkedIn, and Bluesky.

About University Health Network (UHN)

University Health Network embodies Canada’s premier hospital system, comprising ten sites and over 44,000 members. It includes the Toronto General Hospital, Toronto Western Hospital, and the esteemed Princess Margaret Cancer Centre. UHN is recognized as Canada’s top research hospital, playing a crucial role in educational, patient care, and transformative biomedical research efforts spanning diverse medical fields including oncology, neurosciences, and genomic medicine.

Foresight CLARITY™ is intended for research purposes only and is not approved for diagnostic procedures.